Rare Cancer Intelligence
Rare cancers often face limited research visibility, fragmented evidence ecosystems, fewer active clinical trials, and reduced scientific attention despite significant patient need.
CS Cancer Solutions is being developed to bring rare cancer research, biomarker findings, clinical trial activity, reported outcomes, and evidence gaps into a structured research-intelligence framework.
Context
Why Rare Cancer Intelligence Matters
Rare cancers collectively affect millions of patients worldwide, yet many remain underrepresented in research, funding, clinical trials, and evidence development.
Improving visibility into rare cancer research ecosystems can help support research awareness, evidence accessibility, scientific collaboration, and identification of unmet needs across oncology.
Research Visibility
Aggregating and organizing rare cancer research activity into structured intelligence.
Trial Landscape
Mapping clinical trial activity for rare and underrepresented oncology domains.
Biomarker Intelligence
Tracking biomarker developments and molecular evidence in rare cancers.
Research Gaps
Identifying unmet needs and evidence gaps to support scientific prioritization.
CS Cancer Solutions is developing structured cancer intelligence modules for rare and underfinanced malignancies. The proposed framework for cancer-specific evidence summaries includes:
These elements describe the proposed framework for cancer-specific evidence summaries. The framework will be tested and refined as modules are developed.
Evidence Governance Snapshot
- Evidence classification standards in development.
- Scientific and clinical review procedures planned for development and testing.
- Dated updates and version tracking planned for research summaries.
Many rare cancers face limited research funding, fragmented clinical guidance, and fewer active clinical trials despite significant patient need.
CS Cancer Solutions is prioritizing rare and underrepresented cancers as it develops evidence summaries and consistent standards for sourcing, review, and presentation.
The proposed modules are designed to bring together published research, biomarker findings, treatment research, and trial activity to make fragmented evidence easier to explore.
The Ocular (Uveal) Melanoma module is currently live; the other modules are in development based on emerging evidence and institutional priorities.
Cancer-Specific Evidence Summaries are organized as a centralized intelligence hub with category-based navigation:
Each category links to individual cancer-specific modules developed using a consistent evidence framework.
Unlike static guidelines or single-disease registries, these modules are designed to integrate disease biology, molecular evidence, clinical trials, outcomes data, and research gaps into a unified oncology intelligence framework.
Cancer Evidence Summary Categories
Use the categories below to explore structured oncology intelligence modules.
Evidence summaries for prevalent malignancies with extensive research landscapes.
Focused intelligence modules for cancers with limited funding, sparse clinical guidance, or rare incidence.
⭐ Tier 1 Priority (Highest Unmet Need):
Tier 2 Priority:
Tier 3 Priority:
Designed for oncology clinicians, clinical teams, research teams, and cancer program leadership.
Rare cancers often lack clear treatment pathways
Clinical trial discovery is fragmented across global registries
Evidence is scattered and rapidly evolving
This approach is designed to reduce the burden on research teams by organizing cancer evidence in a structured format that supports efficient research evidence review and informed discussion.
The template below outlines intended fields for rare cancer modules as they are developed
Disease Overview
- Definition and classification
- Incidence and rarity
- Typical presentation
- Key prognostic factors
Molecular & Biomarker Landscape
- Key driver mutations
- Prognostic biomarkers
- Molecular subtypes
- Implications for therapy and trials
Evidence-Tiered Treatment Landscape
- Localized Disease: Established interventions
- Advanced/Metastatic Disease: Evidence-based systemic options
- Limitations and controversies
- Evidence Tier noted for each
- Descriptions reflect how treatments are discussed in published literature and guidelines, not recommendations for individual care
Emerging Therapies & Research
- Novel agents
- Targeted approaches
- Immunotherapy insights
- Evidence Tier classification
Clinical Trial Landscape
- Trial focus and mechanism
- Phase and study design
- Geographic distribution (as reported in public registries)
Epidemiology & Outcomes
- Incidence and prevalence
- Survival data (clearly cited)
- Prognostic stratification
Research Gaps & Unmet Needs
- Areas of limited evidence
- Clinical challenges
- Research priorities
Patient-Friendly Summary
- This summary is informational only and is not intended to guide treatment choices or replace consultation with qualified care teams
- What this cancer is
- Why it is challenging
- What research is changing
Evidence Classification & Citations
- Planned evidence classification
- Key sources to be listed (FDA, NCCN, PMIDs, NCTs, etc.)
Required Disclaimers
- Standardized medical and evidence disclaimers
Once additional modules are available, institutions could use Rare & Underfinanced Cancer Evidence Summaries for research purposes without requiring EMR integration or patient-level data.
Potential research uses include:
- Research evidence review for rare and low-incidence cancers
- Clinical-trial landscape research
- Research-gap identification for study planning
- Professional education and fellowship training
These are potential research uses. The platform is not intended for clinical decision support or treatment guidance.
Rare & Underfinanced Cancer Evidence Summaries are planned as part of CS Cancer Solutions' proposed Enterprise and Institutional oncology intelligence offerings, which are under development.
Proposed access levels, currently under development, may eventually include:
- System-wide access across departments
- Custom rare cancer prioritization
- Dedicated research intelligence support
- Advanced analytics and dashboards
- API access for institutional research workflows
Availability, depth, and customization would vary by institutional tier.
Expansion of rare cancer modules is planned based on emerging research, clinical demand, and institutional priorities.
Once an institutional partner program is operating, institutional partners would be able to request prioritization of specific rare or underrepresented cancers based on research focus or regional patient populations.
Medical Disclaimer
Cancer-Specific Evidence Summaries are provided for educational and informational purposes only. They do not constitute medical advice, treatment recommendations, or predictions of individual patient outcomes. All clinical decisions should be made in consultation with qualified healthcare professionals. Evidence tiers and research summaries are subject to change as new data emerges.
Many rare cancer breakthroughs, biomarker discoveries, and early clinical trials originate within federally supported research ecosystems, including NCI-designated cancer centers.
CS Cancer Solutions plans to link research from these environments to rare-cancer evidence summaries as the platform develops.
CS Cancer Solutions is developing a content governance framework for cancer-specific evidence summaries, including source citation, evidence classification, review procedures, and dated updates. The framework will be tested and refined before it is described as an established process.
